Makunts, Tigran
Saunders, Ila M.
Cohen, Isaac V.
Li, Mengxing
Moumedjian, Talar
Issa, Masara A.
Burkhart, Keith
Lee, Peter
Patel, Sandip Pravin
Abagyan, Ruben
Funding for this research was provided by:
Research Participation Program at the U.S. Food and Drug Administration
GM/NIGMS NIH HHS/United States (R35 GM131881)
Article History
Received: 4 May 2021
Accepted: 9 August 2021
First Online: 30 August 2021
Competing interests
: Dr. Patel receives scientific advisory income from: Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, Illumina, Merck, Rakuten, Paradigm, Tempus. Dr. Patel’s university receives research funding from: Bristol-Myers Squibb, Eli Lilly, Incyte, AstraZeneca/MedImmune, Merck, Pfizer, Roche/Genentech, Xcovery. Fate Therapeutics, Genocea, Iovance. Dr. Saunders is currently affiliated with Horizon CME, and has been on advisory boards of Genentech, Partner Therapeutics, and Takeda Inc. All other authors declare no conflict of financial or non-financial interest.